On-Demand Event

Bringing Canadian Guidelines to Life: Recommendations for Hereditary Transthyretin Amyloidosis Polyneuropathy (hATTR PN)

Running time: 1 hour

Planning Committee and Speakers:
Vera Bril, MD, BSc, FRCPC
Michelle Mezei, BSc(Pharm), MDCM, FRCPC

Learning Objectives:

  • Review and understand the recent Canadian Guidelines for Hereditary Transthyretin Amyloidosis Polyneuropathy (hATTR PN) Management
  • Apply guideline recommendations for hATTR PN in their current practice focusing on diagnosis & screening, monitoring, and treatment options

This Webinar is an unaccredited group learning activity approved by the Canadian Neurological Sciences Federation. The program was developed by the Canadian Neurological Sciences Federation and Alnylam Pharmaceuticals and was planned to achieve scientific integrity, objectivity and balance. This Webinar was supported by Alnylam Pharmaceuticals who provided an unrestricted grant and in-kind support.

Language: English